Public Policy Letters, Statements, Legal Briefs, & Other Responses
-
ACMG Comments on FDA Draft Guidance for Products Incorporating Genome Editing
-
Group Sign-on Letter Concerning the VALID Act of 2022 Discussion Draft
-
ACMG Response to Opposing Inclusion of the VALID Act in the FDASLA Act
-
Sign-on Letter Concerning Patent Legislation Negotiation Process
-
Stakeholder Letter Calling for Medicare PFS 3.75% Rate Adjustment Extension
-
Group Sign-On Letter Urging CLIAC to Discuss CLIA Modernization
-
Group Sign-On Letter to CMS Concerning Electronic Funds Transfer Fees on Physicians
-
ACMG Responds to CMS Proposed Rule for CY 2022 PFS and Other Policy Changes (NCD 180.2)
-
Group Sign-On Letter Supporting the VITAL Act
-
Group Letter to Biden Administration Regarding Patent Eligibility Reform